Traws Pharma, Inc. Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted
Traws Pharma, Inc. (TRAW) reported Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted of -$443.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes
us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted · last filed 2026-08-14
- Traws Pharma, Inc. undistributed earnings (loss) allocated to participating securities, diluted for the quarter ending 2026-06-30 was -$443.00K.
- Traws Pharma, Inc. undistributed earnings (loss) allocated to participating securities, diluted for the quarter ending 2026-03-31 was -$1.42M, a 122.09% decline year-over-year.
- Traws Pharma, Inc. undistributed earnings (loss) allocated to participating securities, diluted for the quarter ending 2025-12-31 was -$2.04M.
- Traws Pharma, Inc. undistributed earnings (loss) allocated to participating securities, diluted for the quarter ending 2025-09-30 was -$927.00K.
- Traws Pharma, Inc. undistributed earnings (loss) allocated to participating securities, diluted for fiscal 2025 was $2.31M.
- Traws Pharma, Inc. undistributed earnings (loss) allocated to participating securities, diluted for fiscal 2024 was -$111.85M.
| Period end | Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted 3 month | Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted 6 month | Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted 9 month | Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$443.00K 10-Q · filed 2026-08-14 | -$1.72M 10-Q · filed 2026-08-14 | -$3.90M derived: sum of 3 quarters · filed 2026-08-14 | -$4.83M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$1.42M 10-Q · filed 2026-05-15 | -$3.46M derived: sum of 2 quarters · filed 2026-05-15 | -$4.39M derived: sum of 3 quarters · filed 2026-05-15 | -$4.68M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$2.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | -$2.97M derived: sum of 2 quarters · filed 2026-04-15 | -$3.26M derived: sum of 3 quarters · filed 2026-08-14 | $2.31M 10-K · filed 2026-04-15 |
| 2025-09-30 | -$927.00K 10-Q · filed 2025-11-13 | -$1.22M derived: sum of 2 quarters · filed 2026-08-14 | $4.35M 10-Q · filed 2025-11-13 | -$3.31M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$290.00K 10-Q · filed 2026-08-14 | $5.71M 10-Q · filed 2026-08-14 | -$2.39M derived: sum of 3 quarters · filed 2026-08-14 | -$9.43M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $6.41M 10-Q · filed 2026-05-15 | -$2.10M derived: sum of 2 quarters · filed 2026-05-15 | -$9.14M derived: sum of 3 quarters · filed 2026-05-15 | -$111.51M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$8.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | -$15.54M derived: sum of 2 quarters · filed 2026-04-15 | -$117.91M derived: sum of 3 quarters · filed 2026-04-15 | -$111.85M 10-K · filed 2026-04-15 |
| 2024-09-30 | -$7.04M 10-Q · filed 2025-11-13 | -$109.41M derived: sum of 2 quarters · filed 2025-11-13 | -$103.35M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | -$102.37M 10-Q · filed 2025-08-14 | -$93.41M 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |